Brought to you by 
Merck, Tularik screen for HIV, herpes, HPV drugs
07 May 2002
Executive Summary
Tularik (transcription factors) and Merck agreed to work together on up to six anti-viral targets for which Tularik has set up assays and which it will use as screens against its own chemical library and Merck's.
Deal Industry
- Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck, Tularik screen for HIV, herpes, HPV drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice